Allworth Financial LP Has $226,000 Stake in Invesco Pharmaceuticals ETF (NYSEARCA:PJP)

Allworth Financial LP reduced its holdings in shares of Invesco Pharmaceuticals ETF (NYSEARCA:PJP) by 14.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,701 shares of the company’s stock after selling 466 shares during the period. Allworth Financial LP owned 0.08% of Invesco Pharmaceuticals ETF worth $226,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. Jane Street Group LLC acquired a new position in shares of Invesco Pharmaceuticals ETF during the third quarter valued at about $1,163,000. Arete Wealth Advisors LLC acquired a new position in Invesco Pharmaceuticals ETF during the 3rd quarter worth approximately $402,000. Grimes & Company Inc. bought a new position in Invesco Pharmaceuticals ETF in the fourth quarter worth approximately $354,000. JPMorgan Chase & Co. grew its stake in Invesco Pharmaceuticals ETF by 241.7% in the third quarter. JPMorgan Chase & Co. now owns 4,046 shares of the company’s stock valued at $352,000 after acquiring an additional 2,862 shares during the period. Finally, MGB Wealth Management LLC increased its holdings in shares of Invesco Pharmaceuticals ETF by 11.9% during the fourth quarter. MGB Wealth Management LLC now owns 21,976 shares of the company’s stock valued at $1,815,000 after acquiring an additional 2,345 shares in the last quarter.

Invesco Pharmaceuticals ETF Stock Down 0.4 %

Shares of NYSEARCA:PJP opened at $86.54 on Friday. Invesco Pharmaceuticals ETF has a twelve month low of $75.33 and a twelve month high of $89.87. The stock’s 50 day moving average is $84.40 and its 200-day moving average is $85.89. The firm has a market capitalization of $263.95 million, a price-to-earnings ratio of 24.54 and a beta of 0.58.

About Invesco Pharmaceuticals ETF

PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.